Atlas Trials

Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity

2 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity

RecordFirmDate
Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status (NCT02983799)AstraZeneca2016-12-22
Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments (NCT02282020)AstraZeneca2015-02-06

Track Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity automatically

Every clearance here is in the API, with alerts when new ones post.